कंपनी का अवलोकन
enVVeno Medical Corporation is a clinical-stage medical device company dedicated to advancing the standard of care for venous disease through the development of bioprosthetic tissue-based solutions. The corporation operates within the broader Healthcare sector, specifically focusing on the Medical Devices industry, which involves the manufacturing and commercialization of equipment and supplies used for medical diagnosis, treatment, or prevention. This entity employs a workforce of 33 individuals and holds a market capitalization of $6.77M, with reported annual revenue figures marked as unavailable for the trailing twelve months. The market cap of $6.77M combined with the lack of disclosed annual revenue indicates that the company is a micro-cap entity with limited historical financial data available for public analysis. The employee count of 33 suggests a highly lean organizational structure typical of early-stage biotechnology and medical device firms where capital is directed toward research and product development rather than extensive administrative overhead.
वित्तीय स्वास्थ्य
The company's financial performance for the trailing twelve months shows a Net Income of $-19,472,000 and an EBITDA of $-20,763,000, while revenue data is not disclosed. The significant gap between the unavailable revenue figure and the substantial net loss of $-19,472,000 reveals that the company is in a heavy investment phase where operating expenses and research costs far exceed any current income generation. Free cash flow stands at $-9,209,875, indicating that the company is burning through its cash reserves to fund its clinical-stage operations and product development pipeline. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, which signifies that the company has not yet achieved consistent profitability or positive gross margins on a commercial scale. The balance sheet shows a Cash position of $28.21M against a Debt obligation of $700,000, resulting in a Debt to Equity ratio of 2.58. Despite the high debt-to-equity figure, the substantial cash reserve provides a conservative buffer against short-term liquidity needs, though the leverage ratio suggests equity dilution may occur if additional funding is required. The Current Ratio is listed at 13.58, which indicates an extremely strong short-term liquidity position where current assets vastly exceed current liabilities. Return on Equity is -56.2% and Return on Assets is -35.1%, metrics that reveal management is currently destroying shareholder value per the standard accounting definitions due to significant losses, a common characteristic of clinical-stage companies prior to product approval or commercial launch.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to the negative earnings, while the Forward P/E is listed at -8.68, implying that the market expects earnings to remain negative or that valuation models using forward multiples are not applicable in the traditional sense for this stage of development. The Price to Book ratio is 0.25, indicating that the stock trades at a significant discount to its book value, which often reflects market skepticism regarding the recoverability of assets or the high risk of the clinical-stage pipeline. The Price to Sales ratio is N/A because revenue data is unavailable, and the EV/EBITDA is 1.00, a metric that is low but distorted by the negative earnings and the absence of standard revenue figures for comparison. The 52-week high is $196.70 and the 52-week low is $8.67, placing the current price context within a highly volatile trading range of over 2200 percent. Given the current market data does not specify the exact share price, the stock's position relative to the 52-week range remains indeterminate without the current trading price, though the wide range suggests extreme price sensitivity. The Beta value is 1.09, meaning the stock exhibits slightly higher price volatility relative to the broader market, moving approximately 9 percent more than the overall market index in response to general market fluctuations.
Growth & Income
The Revenue Growth year-over-year and Earnings Growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue at this stage of the company's lifecycle. As the dividend yield is N/A and the Payout Ratio is 0.0%, the company does not distribute dividends to shareholders. This non-dividend status indicates that the company retains all available earnings, if any, or reinvests its limited cash resources directly into research, clinical trials, and the development of the VenoValve product rather than paying income to investors. The overall growth and income profile is characterized by a lack of historical revenue growth data and zero dividend income, reflecting the strategic choice to prioritize product development and market entry over current shareholder returns.